Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment
article
OA: bronze
CC0
⤵ 5 in-corpus citations
AI-generated summary
Linzagolix treatment for 12 months effectively reduced endometriosis-associated pain and improved quality of life in patients with no significant safety concerns.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (6)
- Low-energy extracorporeal shock wave therapy is associated with reduced inflammation and fibrosis in an E2-induced rat model of endometriosis and remains effective under menopause-mimicking conditions 2026
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Hormonal drugs for the treatment of endometriosis 2022
- Linzagolix: First Approval 2022
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
- The oral gonadotropin-releasing hormone antagonists: contemporary possibilities and perspectives of application 2020
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK